Yantai Dongcheng Pharmaceutical Group Co.,Ltd.

SZSE:002675 Rapporto sulle azioni

Cap. di mercato: CN¥10.9b

Yantai Dongcheng Pharmaceutical GroupLtd Crescita futura

Future criteri di controllo 3/6

Yantai Dongcheng Pharmaceutical GroupLtd is forecast to grow earnings and revenue by 45.9% and 13.1% per annum respectively. EPS is expected to grow by 45.8% per annum. Return on equity is forecast to be 7.6% in 3 years.

Informazioni chiave

45.9%

Tasso di crescita degli utili

45.8%

Tasso di crescita dell'EPS

Biotechs crescita degli utili44.8%
Tasso di crescita dei ricavi13.1%
Rendimento futuro del capitale proprio7.6%
Copertura analitica

Good

Ultimo aggiornamento01 Nov 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

Yantai Dongcheng Pharmaceutical GroupLtd (SZSE:002675) Has A Pretty Healthy Balance Sheet

Aug 23
Yantai Dongcheng Pharmaceutical GroupLtd (SZSE:002675) Has A Pretty Healthy Balance Sheet

Yantai Dongcheng Pharmaceutical Group Co.,Ltd.'s (SZSE:002675) Business Is Yet to Catch Up With Its Share Price

Jul 12
Yantai Dongcheng Pharmaceutical Group Co.,Ltd.'s (SZSE:002675) Business Is Yet to Catch Up With Its Share Price

News Flash: 7 Analysts Think Yantai Dongcheng Pharmaceutical Group Co.,Ltd. (SZSE:002675) Earnings Are Under Threat

May 06
News Flash: 7 Analysts Think Yantai Dongcheng Pharmaceutical Group Co.,Ltd. (SZSE:002675) Earnings Are Under Threat

Yantai Dongcheng Pharmaceutical GroupLtd's (SZSE:002675) Problems Go Beyond Weak Profit

May 05
Yantai Dongcheng Pharmaceutical GroupLtd's (SZSE:002675) Problems Go Beyond Weak Profit

Is Yantai Dongcheng Pharmaceutical GroupLtd (SZSE:002675) A Risky Investment?

Mar 15
Is Yantai Dongcheng Pharmaceutical GroupLtd (SZSE:002675) A Risky Investment?

Yantai Dongcheng Pharmaceutical Group Co.,Ltd.'s (SZSE:002675) P/E Is On The Mark

Feb 27
Yantai Dongcheng Pharmaceutical Group Co.,Ltd.'s (SZSE:002675) P/E Is On The Mark

Previsioni di crescita degli utili e dei ricavi

SZSE:002675 - Stime future degli analisti e dati finanziari passati (CNY Millions )
DataRicaviGuadagniFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
12/31/20263,906424N/A7605
12/31/20253,452327N/A6646
12/31/20243,119258N/A6486
9/30/20242,85391-167362N/A
6/30/20242,911137-280247N/A
3/31/20243,072224-340204N/A
12/31/20233,276210-235277N/A
9/30/20233,42726335490N/A
6/30/20233,603323199664N/A
3/31/20233,554302467853N/A
1/1/20233,583307607997N/A
9/30/20223,858220415986N/A
6/30/20223,851165292833N/A
3/31/20223,902140295846N/A
1/1/20223,912152413944N/A
9/30/20213,637341445788N/A
6/30/20213,5993537021,023N/A
3/31/20213,596411333618N/A
12/31/20203,419418310573N/A
9/30/20203,395214339645N/A
6/30/20203,312196149443N/A
3/31/20203,172164508760N/A
12/31/20192,993155446696N/A
9/30/20192,877366335500N/A
6/30/20192,709347458577N/A
3/31/20192,467302305457N/A
12/31/20182,333280372493N/A
9/30/20182,098228458600N/A
6/30/20181,842212N/A444N/A
3/31/20181,679185N/A339N/A
12/31/20171,596173N/A209N/A
9/30/20171,511172N/A79N/A
6/30/20171,377149N/A106N/A
3/31/20171,245145N/A106N/A
12/31/20161,158131N/A196N/A
9/30/20161,014119N/A210N/A
6/30/201690395N/A109N/A
3/31/201685283N/A103N/A
12/31/201579590N/A67N/A
9/30/201572594N/A36N/A
6/30/201572499N/A40N/A
3/31/2015727103N/A-16N/A
12/31/2014751104N/A52N/A
9/30/201478699N/A2N/A
6/30/201478396N/A-10N/A
3/31/201478291N/A66N/A
12/31/2013775101N/A-21N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: 002675's forecast earnings growth (45.9% per year) is above the savings rate (2.9%).

Guadagni vs Mercato: 002675's earnings (45.9% per year) are forecast to grow faster than the CN market (25.8% per year).

Guadagni ad alta crescita: 002675's earnings are expected to grow significantly over the next 3 years.

Ricavi vs Mercato: 002675's revenue (13.1% per year) is forecast to grow slower than the CN market (14% per year).

Ricavi ad alta crescita: 002675's revenue (13.1% per year) is forecast to grow slower than 20% per year.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: 002675's Return on Equity is forecast to be low in 3 years time (7.6%).

Scoprire le aziende in crescita

7D

1Y

7D

1Y

7D

1Y